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Sul'nmary 
An effective vaccine against the human immunodeficiency virus should be capable of eliciting 
both an antibody and a cytotoxic T lymphocyte (CTL) response. However, when viral proteins 
and peptides are formulated with traditional immunological adjuvants and inoculated via a route 
acceptable for use in humans, they have not been successful at eliciting virus-specific, major 
histocompatibility complex (MHC) class I-restricted CTL. We have designed a novel viral subunit 
vaccine by encapsulating  a previously  defined synthetic peptide CTL  epitope  of the simian 
immunodeficiency virus (SIV) gag protein within a proteoliposome capable of attaching to and 
fusing with plasma membranes. Upon fusing, the encapsulated contents of this proteoliposome 
can enter the MHC class I processing pathway through the cytoplasm. In this report, we show 
that after a single intramuscular vaccination,  rhesus monkeys develop a CD8 + cell-mediated, 
MHC class I-restricted CTL response that recognizes the synthetic peptide immunogen. The 
induced CTL also demonstrate antiviral immunity by recognizing SIV gag protein endogenously 
processed by target cells infected with SIV/vaccinia recombinant virus. These results demonstrate 
that virus-specific, MHC class I-restricted, CD8 + CTL can be elicited by a safe, nonreplicating 
viral subunit vaccine in a primate model for acquired immune deficiency syndrome. Moreover, 
the proteoliposome vaccine formation described can include multiple synthetic peptide epitopes, 
and, thus, offers a simple means of generating antiviral cell-mediated immunity in a genetically 
heterogeneous  population. 
T 
he simian immunodeficiency  virus (SIV)/macaque monkey 
model of AIDS provides an important system for evalu- 
ating HIV vaccines. Protective immunity against a cell-free 
AIDS virus infection has previously been demonstrated in 
this model using inactivated whole virus vaccines (1, 2). How- 
ever, perhaps because inactivated virus vaccines are not likely 
to induce CTL, this approach has resulted in only partial pro- 
tection of monkeys from cell-associated SIV challenge (3). 
More recently, Hu et al. (4) have demonstrated protection 
against SIV using a combination of a live recombinant SIV/vac- 
cinia virus followed  by recombinant SIV env protein. Although 
live vectors can induce CTL (5), there may be a safety risk 
involved in the large scale use of some vaccines of this type 
(6, 7). Thus, we sought to develop a strategy for inducing 
SIV-specific  MHC class I-restricted CTL through the use of 
a nonreplicating subunit vaccine. 
MHC class I antigen presentation  generally occurs only 
for antigens synthesized and processed within a cell (8). How- 
ever, early studies had shown that viral antigens of replication- 
inactivated fusogenic enveloped viruses could be presented 
by MHC class I molecules (9). More recently it has been 
demonstrated that exogenous protein antigens can be presented 
by MHC class I molecules if these antigens are introduced 
directly into the cytoplasm without entering the endosomal/ 
lysosomal degradation pathway (10, 11). Our laboratory has 
developed  procedures for preparing large unilamellar liposomes 
with biologically active Sendai or influenza glycoproteins in- 
corporated into the liposome bilayer (12). The glycoproteins 
enable these proteoliposomes  to deliver drugs, proteins, and 
nucleic acids directly into the cytoplasm of cells either in vitro 
or in vivo (13). These proteoliposomes can therefore introduce 
encapsulated antigen directly into the cytoplasm for subse- 
quent presentation  by MHC class I molecules. 
Previously we have shown that  SIVmac-infected rhesus 
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A*01,  develop  a  gag-specific  CD8 +  CTL  response  that 
recognizes a nine-amino acid epitope of gag p27, and is re- 
stricted by Mamu-A*Ol  (14).  In the present  study, we have 
assessed whether a 12-amino acid synthetic peptide (peptide 
11C) containing this CTL epitope induces a MHC class I-re- 
stricted CTL response in rhesus monkeys when noncovalently 
encapsulated within  a proteoliposome capable of fusing  to 
cellular membranes. 
Materials  and Methods 
Animals.  Heparinized blood was  obtained from immunized 
rhesus monkeys (Macaca mulatta) every other week. 
Cell Lines.  Rhesus monkey B-lymphoblastoid cell lines (B-LCL) 
were  generated  by  incubating  105  Ficoll-diatrizoate-isolated 
PBMC with  100/~1 of $594.  $594 is a cell line productively in- 
fected with the transforming herpesvirus Herpes  papio. The B-LCL 
were maintained in antibiotic-supplemented RPMI  1640 (Gibco 
Laboratories, Grand Island, NY) containing 10% FCS (Flow Labora- 
tories,  McLean,  VA). 
One-dimensional(I-D)IEE  This technique has been completely 
described (16). Briefly,  5  x  106 B-LCL from a group of rhesus 
monkeys were metabolically labeled  and MHC dass I molecules 
were immunoprecipitated  with a human MHC class 1-specific mAb. 
These precipitates  were phase separated using Triton X-114 extrac- 
tion and then treated with neuraminidase (type VI; Sigma Chem- 
ical Co., St. Louis, MO) to remove sialic acid residues. Finally, the 
precipitates  were subjected  to 1-D IEF under reducing conditions 
and an autoradiograph was  prepared. 
Immunogen  Formulations.  Unmodified  liposomes:  large  uni- 
lamellar phosphatidyl serine/cholesterol (9:1 weight ratio) vesicles 
containing buffer, with or without peptide 11(], were prepared by 
direct addition of  EDTA to lipid cochleates (15). Sendai proteolipo- 
somes:  the  envelope  glycoproteins  and  lipids  of Sendal  virus 
(parainfluenza type I) were extracted, converted to lipid protein 
cochleates,  then to proteoliposomes by direct addition of EDTA 
(15).  Vaccinations  contained  100  /xg  of peptide  llC  (EGCT- 
PYDINQML) encapsulated in 1.5 mg lipid. The peptide llC used 
to immunize was synthesized using a stepwise solid-phase method 
and subsequently HPLC purified. 
In Vitro Restimulation of T Cells.  5-12  x  106 FicoU-diatrizoate 
(Sigma Chemical Co.)-isolated PBMC were placed in 2 ml of RPMI 
containing 20% FCS and 10/xg/ml of peptide llC (Multiple Pep- 
tide Systems, San Diego, CA) in a 12-well plate.  On day 3, 2  x 
107 mitomycin C (Sigma Chemical Co.)-treated autologous 7-10- 
d-old Con A (Sigma Chemical Co.)-activated rlL-2 (Hoffman-La 
Roche, Inc., Nutley, NJ)-expanded cells were pulsed with 50/~g/ml 
peptide 11C in 300/zl and then added to the cultures along with 
2 ml of RPMI/20% FCS and 40 U/ml of rib2. Cells were main- 
tained for a total of 9-11  d before the assay. Dead cells were re- 
moved by Ficoll-Diatrizoate centrifugation. 
Cytotoxicity Assay.  Target cells were either autologous (Mm 
90 and Mm 211) or Mamu-A*01 +  allogeneic H. papio-immortal- 
ized B-LCL incubated at 37~  with 50/~g/ml of peptide 11B (AL- 
SEGCTPYDIN)  or  11C  and  0.50  mCi/ml  Na2SlCrO4 (ICN 
Laboratories,  Irvine, CA) for 16 h and then washed twice. Target 
cells were plated at 104 cells per well and effector cells were added 
at various E/T ratios.  These cell mixtures were incubated for 4 h 
at 37~  Percent peptide 11C-specific lysis is calculated as percent 
specific lysis of peptide 11C-pulsed target cells minus the percent 
specific lysis of peptide liB-pulsed target cells. Percent specific lysis 
is calculated  as:  100x  (experimental release  -  spontaneous re- 
lease)/(maximum release -  spontaneous  release). All experimental 
values were calculated in duplicate while control releases were done 
in quadruplicate. 
CD8*  Cell Depletion.  2 d before the assay, CD8 § cells were 
isolated by incubating the cultured cells with an anti-CD8 mAb 
(TPT3F9,  I:400 dilution of ascites;  S.  Schlossman,  Dana Farber 
Cancer Institute, Boston, MA) followed by immunomagnetic bead 
separation (Dynal, Oslo, Norway) using a bead-to-cell ratio of 40:1. 
Just before the assay the magnetic beads  were removed from the 
CD8 + cells. The live cells were then isolated by Ficoll-Diatrizoate 
density centrifugation. The CD8-depleted population contained 
<5% containing CD8 + cells as assessed by flow cytometry (data 
not  shown). 
Results and Discussion 
As peptide llC-specific CTL are restricted by the MHC 
class I molecule Mamu-A*01,  the MHC class I phenotype of 
a  group of rhesus  monkeys was  assessed in order to sdect 
potential responder animals for peptide llC immunization, 
1-D IEF was used to identify rhesus monkeys expressing Mamu- 
A*01  by comparing  the  migration  of immunoprecipitated 
Figure 1.  1-D IEF analysis of the MHC class I molecules of a group 
of rhesus monkeys. Lysates  were subjected to electrophoresis  over a pH 
gradient of 5-7. The first seven  lanes represent  animals expressing  the MHC 
class I molecule  Mamu-A*01, with Mm 177 having  been previously  defined; 
the last two lanes represent two Mamu-A*Ol -  animals. The positions of 
Mamu-A*0I and/92-microglobulin are indicated with arrows. 
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Figure 2.  PBMC  from Mamu-A*Ol + rhesus monkeys immunized with 
peptide 11C in Sendal proteoliposomes  develop peptide 11C-specific  lytic 
activity. (A) Two Marau-A*O1 + rhesus monkeys (Mm 91 and 138) were 
immunized with 100/zg of peptide 11C encapsulated  in unmodified  lipo- 
somes and two Marau-A'Ol + animals (Mm 59 and 347) were immunized 
with the same liposomes without peptide intramuscularly at weeks 0, 6, 
and 32 (see arrows marked L). At weeks 36 and 40, similar immuniza- 
tions were done utilizing proteoliposomes  containing the attachment and 
fusion glycoproteins of Sendai virus (see arrows marked S PL). PBMC 
were isolated at the times indicated, restimulated in vitro, and the cyto- 
toxicity assay  performed. (B) Restimulated effector  cells  from two Mamu- 
A*OI + (Mm 8 and 196) and two Mamu-A*O1 -  (Mm 90 and 211) rhesus 
monkeys immunized intramuscularly with 100/zg of peptide 11C encap- 
sulated in Sendai proteoliposomes  at weeks 0 and 4 (see arrows marked 
S  PL) were assessed for peptide 11C-specific  cell lysis at weeks -1, 1, 
3, 5, and 6. E/T cell ratio was 50:1 for all studies. NT, not tested. 
MHC class I molecules from B-LCL of a cohort of animals 
to that of the previously characterized SIV-infected, Mamu- 
A*01 + rhesus monkey Mm 177.  Six Mamu-A*01 + animals 
were identified for immunization studies (Fig. 1). These results 
were confirmed by demonstrating  the  capacity of peptide 
11C-specific CTL from Mm 177 to lyse peptide 11C-pulsed 
B-LCL derived from the  six monkeys (data not  shown). 
Initially, two Mamu-A*01 + rhesus monkeys (Mm 91 and 
138) were immunized three times intramuscularly with 100 
#g of peptide 11C encapsulated in unmodified liposomes, while 
two Mamu-A*Ol +  monkeys (Mm 59 and 347) were given 
unmodified liposomes without peptide according to a similar 
schedule. As shown in Fig.  2  A,  left, peptide 11C-restimu- 
lated cultures of PBMC from these animals did not develop 
any detectable peptide  11C-specific lyric activity. Similarly 
restimulated PBMC from the SIV-infected animal Mm 177 
reproducibly demonstrated peptide 11C-specific CTL activity 
(data not  shown). 
The immunogenicity of peptide 11C encapsulated within 
fusogenic liposomes containing  the attachment  and fusion 
glycoproteins of Sendai virus was assessed in the same monkeys 
that previously failed to respond to peptide 11C encapsulated 
in unmodified liposomes. The PBMC from monkeys receiving 
100/~g of peptide 11C in the Sendai proteoliposome formu- 
lation  demonstrated  a peptide  11C-specific lytic response, 
whereas those animals receiving the empty proteoliposomes 
did not (Fig.  2  A,  right).  These results were confirmed by 
immunizing  a second group of naive animals,  two Mamu- 
A*01 + (Mm 8 and 196) and two Mamu-A*01 -  (Mm 90 and 
211), with identical peptide 11C/Sendai proteoliposome for- 
mulations  (Fig.  2  B).  All  four  peptide  llC/proteolipo- 
some-immunized  Mamu-A*Ol +  rhesus monkeys developed 
peptide-specific lytic responses within 2 wk of primary im- 
munization.  The peptide-specific lytic activity was demon- 
strable >2 mo after the final immunization  and was consis- 
tently demonstrated over the period in which the assays were 
performed  (data not  shown). 
The peptide-specific effector cells generated in the peptide 
11C/proteoliposome-immunized Mamu-A*01 + animals  were 
CD8 +, MHC class I-restricted CTL. Rhesus monkeys not 
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two immunizations with the immunogenic peptide 11C/pro- 
teoliposome (Fig.  2 B).  In  addition,  PBMC from peptide 
11C/proteoliposome-immunized  Mamu-A *01 +  monkeys 
were able to lyse either  peptide  11C-pulsed Mamu-A*01 + 
rhesus monkey allogeneic B-LCL or a human B cell line stably 
transfected with Mamu-A'01,  but not  cell lines  that  were 
Mamu-A*01-  (Table  1).  Finally,  effector cell  populations 
depleted of CD8 + cells by antibody/immunobead selection 
demonstrated no peptide 11C-specific lytic activity, while the 
purified  CD8 + cells exhibited enriched  activity (Fig.  3). 
The capacity of this vaccine to generate CTL that would 
recognize vitally infected cells was assessed using target cells 
infected with vaccinia recombinants containing the SIVmac251 
gag  gene.  As shown in  Fig.  4,  PBMC from all  four pep- 
tide/proteoliposome-immunized  Mamu.A*01 + animals  were 
able to lyse target cells expressing the SIVmac gag epitope 
as a result of vaccinia/SIVmac gag recombinant infection and 
endogenous antigen processing. These effector cells did not 
lyse target cells infected with a control vaccinia construct. 
The  gag-specific  lytic  activity  was  not  present  in  pllC- 
restimulated PBMC of these animals before immunization 
(data not  shown). 
The  induction  of CD8 +,  MHC class  I-restricted  CTL 
specific for SIVmac gag using the relatively hydrophilic SIVmac 
gag peptide  11C requires that  the peptide be encapsulated 
within liposomes containing the attachment and fusion pro- 
teins of Sendai virus integrated into the liposome bilayer. This 
observation together with previous demonstrations of prepa- 
rations  that  induce  CD8 +  CTL  (15-19)  suggest  that  the 
minimal  immunogenic  formulation  for  the  elicitation  of 
CD8 + CTL includes:  (a) a peptide that represents a MHC 
class I epitope; (b) a component that enhances uptake by the 
MHC dass I-presenting cells of the reticuloendothelial  system; 
and (c) properties that can compromise the integrity of a lipid 
bilayer,  facilitating delivery of the antigen directly into the 
cytoplasm. The observation that an OVA peptide can induce 
CD8 + CTL in mice after intravenous administration  in sa- 
line appears to be an exception to this paradigm (20). How- 
ever, the amino terminus of this OVA peptide epitope is highly 
hydrophobic and has  special  membrane-perturbing  charac- 
teristics that may subserve all of these postulated immuno- 
genic  requirements.  We have had  similar  results  inducing 
CD8 + CTL in mice using a strongly amphipathic HIV pep- 
tide epitope encapsulated in liposomes without the inclusion 
of Sendai glycoproteins (our unpublished observations). How- 
Table  1.  Peptide  1IC/Proteoliposorae-induced  CTL Are Restricted  by the Rhesus Monkey MHC  Class I  Molecule Mamu-A*01 
Target cell lines* 
Mamu-A "01 +  Mamu-A *01 - 
Mm  164  Mm 210  221(A1)  Mm 90  .221 
Effector cells  s  E/T ratio*  11B  11C  11B  11C  11B  11C  11B  11C  11B  11C 
Mm  138  40:1  11  40  6  27  12  32  1  3  5  5 
(p11C  Imm.)  20:1  8  23  -4  19  6  21  5  9  4  4 
10:1  3  11  0  8  4  12  6  6  3  4 
Mm 8  40:1  7  41  5  23  15  42  3  8  12  10 
(p11C  hnm.)  20:1  2  26  8  19  4  39  2  5  8  6 
10:1  2  17  7  12  7  20  0  2  5  6 
Mm 59  40:1  1  -3  3  4  10  8 
(control  Imm.)  20:1  -  2  0  2  2  6  4 
10:1  -  5  -  1  3  1  5  3 
Mm  177  8:1  0  51  2  50  -2  41  -5  3  2  1 
(SIV infected)  4:1  - 2  48  1  39  -  1  31  0  1  0  2 
2:1  0  33  1  27  -  1  23  -  2  0  1  2 
* Target cells were Marau-A *01 + rhesus monkey allogeneic B-LCL (Mm 164 and 210), a Marau.A *01-transfected human EBV-immortalized B call 
line .221(A1)(14), the untransfected  .221 (25), and a Mamu-A*01-  rhesus monkey allogeneic B-LCL (Mm 90). All target  cells were either pulsed 
with peptide  11B or 11C. 
* E/T cell ratio. 
S Effector cells were peptide 11C-restimulated  PBMC from peptide 11C/proteoliposome~immunized  animals Mm 138 and 8 obtained at 41 and 11 
wk after  primary immunization, respectively; from proteoliposome  control immunized animal Mm 59 at 41 wk;  and from the Marau-A'01 +, 
SIVmac251-infected animal Mm 177 at 2 yr postinfection. 
~l Percent  specific release. 
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Figure 3.  Peptide  11C-specific  lysis is mediated by CD8 + cells. PBMC 
from all four Mamu.A*Ol + peptide-immunized rhesus monkeys were re- 
stimulated in vitro and were separated into CD8 + (circles) and CDS- (tri- 
angles)  populations. Target cells were a Marau-A*01 + allogeneic rhesus 
B-LCL pulsed with peptide 11C {filled symbols)  or 11B (open symbols). 
ever, the majority of CTL peptide epitopes do not have such 
unusual properties and, thus, will require an appropriate for- 
mulation  to reliably induce CD8 + CTL.  The proteolipo- 
some formulation  defined in  the present  study meets this 
objective without toxicity or inflammation in multiply im- 
munized rhesus monkeys and with the ease of intramuscular 
administration. 
Although  recombinant  HIV  gp160  has  been  used  to 
generate virus-specific  CTL in mice (16), this study represents 
the first example of a viral subunit vaccination inducing CTL 
in an established model for HIV infection of humans.  The 
use of peptide immunogens as a vaccination against HIV is 
attractive, as only those epitopes contributing to a beneficial 
immune response can be included, eliminating the possibility 
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Figure 4.  SIVmac  gag-expressing targets were lysed  by peptide llC-re- 
stimulated CTL from peptide/pmteoliposome-immunized  rhesus monkeys. 
Target cells were prepared by infecting a Marau-A*Ol  + allogeneic  B-LCL 
with previously  described (26) vaccinia recombinants expressing SIVmac 
gag or an irrelevant protein using a multiplicity of infection of 20 for 
16 h before the assay. E/T cell ratios were as indicated. 
that immunization might enhance viral infectivity or induce 
autoreactivity (21, 22). Although the immunogenicity of a 
given peptide is dependent on the MHC of an individual, 
peptides corresponding to many defined epitope/MHC com- 
binations  (23) can be easily synthesized.  Moreover, hyper- 
variable epitopes can be accommodated by synthesizing mul- 
tiple peptides corresponding to divergent virus strains.  The 
Sendai proteoliposome encapsulation technique that we have 
employed is quite suitable for encapsulating cocktails of un- 
modified viral peptides and, thus, provides a simple method 
of generating MHC class I-restricted cellular immunity in 
outbred populations. In addition,  these proteoliposome for- 
mulations can induce humoral immunity when B and T helper 
cell epitopes are covalently linked to phospholipids incorpo- 
rated within the lipid bilayer (24). These flexible features of 
peptide/proteoliposomes as immunogens support the poten- 
tial utility of this vaccination approach for the control of HIV 
and other infections in humans. 
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